Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Gluconic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gluconic Acid SCHEMBL29089144 | 0.98 | PDE4A (0.76) | PDE4ALMNAUSP2SLCO1B1TP53 | |
| Gluconic Acid SCHEMBL27466658 | 0.98 | PDE4A (0.83) | PDE4ALMNAUSP2SLCO1B1TP53 | |
| Gluconic Acid SCHEMBL30528009 | 0.98 | PDE4A (0.83) | PDE4ALMNAUSP2SLCO1B1TP53 | |
| Gluconic Acid SCHEMBL872998 | 0.98 | PDE4A (0.83) | PDE4ALMNAUSP2SLCO1B1TP53 | |
| Gluconic Acid SCHEMBL27816908 | 0.96 | PDE4A (0.79) | PDE4ALMNAUSP2SLCO1B1TP53 | |
| Gluconic Acid SCHEMBL5095328 | 0.96 | PDE4A (0.79) | PDE4ALMNAUSP2SLCO1B1TP53 | |
| Gluconic Acid SCHEMBL20298871 | 0.96 | PDE4A (0.79) | PDE4ALMNAUSP2SLCO1B1TP53 | |
| Gluconic Acid SCHEMBL25311486 | 0.94 | PDE4A (0.76) | PDE4ALMNAUSP2SLCO1B1TP53 | |
| Gluconic Acid SCHEMBL377416 | 0.94 | PDE4A (0.76) | PDE4ALMNAUSP2SLCO1B1TP53 | |
| Gluconic Acid SCHEMBL4165306 | 0.94 | PDE4A (0.76) | PDE4ALMNAUSP2SLCO1B1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197853-A1 | METHODS AND COMPOSITIONS OF TREATING CANCER | PHARMACYCLICS, INC. (US) | 2009-08-06 | — | — | US | claimed |
| EP-1486199-B1 | Alcoholic aerosol deodorant composition containing zinc salicylate | OREAL (FR) | 2007-10-17 | — | — | EP | claimed |
| WO-2007059329-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER | PHARMACYCLICS, INC. (US) | 2007-05-24 | — | — | WO | claimed |
| US-20090197853-A1 | METHODS AND COMPOSITIONS OF TREATING CANCER | PHARMACYCLICS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| EP-1845998-A4 | A METHOD FOR TREATING NEUROLOGIC DISEASES | PHARMACYCLICS INC (US) | 2008-06-18 | — | — | EP | disclosed |
| EP-1845998-A2 | A METHOD FOR TREATING NEUROLOGIC DISEASES | Pharmacyclics, Inc. (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2007059329-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER | PHARMACYCLICS, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2006078875-A2 | A METHOD FOR TREATING NEUROLOGIC DISEASES | PHARMACYCLICS, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| US-20060160784-A1 | Method for treating neurologic diseases | PHARMACYCLICS, INC. | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160784-A1 | Method for treating neurologic diseases | SOD1, CLN6, SMN1; SMN2 | PDE4A 3424/4885LMNA 1303/4885USP2 1835/4885 |
| US-20090197853-A1 | METHODS AND COMPOSITIONS OF TREATING CANCER | SOD3, TSG101, GPX4 | PDE4A 4627/4885LMNA 1680/4885USP2 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.